These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 34987609)

  • 21. Helicobacter pylori therapy: a paradigm shift.
    Graham DY; Dore MP
    Expert Rev Anti Infect Ther; 2016 Jun; 14(6):577-85. PubMed ID: 27077447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toward population specific and personalized treatment of Helicobacter pylori infection.
    Liou JM; Chen PY; Kuo YT; Wu MS;
    J Biomed Sci; 2018 Oct; 25(1):70. PubMed ID: 30285834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018.
    Pellicano R; Zagari RM; Zhang S; Saracco GM; Moss SF
    Minerva Gastroenterol Dietol; 2018 Sep; 64(3):310-321. PubMed ID: 29600697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship.
    Graham DY; Liou JM
    Clin Gastroenterol Hepatol; 2022 May; 20(5):973-983.e1. PubMed ID: 33775895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study.
    Pilotto A; Franceschi M; Rassu M; Leandro G; Bozzola L; Furlan F; Di Mario F
    Dig Liver Dis; 2000 Nov; 32(8):667-72. PubMed ID: 11142574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.
    Cao Z; Chen Q; Zhang W; Liang X; Liao J; Liu W; Xiao S; Lu H
    Scand J Gastroenterol; 2015; 50(10):1185-90. PubMed ID: 25881966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
    Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Helicobacter pylori: A Review of Current Diagnostic and Management Strategies.
    Guevara B; Cogdill AG
    Dig Dis Sci; 2020 Jul; 65(7):1917-1931. PubMed ID: 32170476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Helicobacter pylori-related diseases.
    Gisbert JP
    Gastroenterol Hepatol; 2016 Sep; 39 Suppl 1():36-46. PubMed ID: 27888863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States.
    Yunusa I; Love BL
    Am J Gastroenterol; 2023 Apr; 118(4):635-644. PubMed ID: 36693030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Culture With Antibiogram to Next-Generation Sequencing Using Bacterial Isolates and Formalin-Fixed, Paraffin-Embedded Gastric Biopsies.
    Hulten KG; Genta RM; Kalfus IN; Zhou Y; Zhang H; Graham DY
    Gastroenterology; 2021 Nov; 161(5):1433-1442.e2. PubMed ID: 34293298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High prevalence and risk factors of multiple antibiotic resistance in patients who fail first-line Helicobacter pylori therapy in southern China: a municipality-wide, multicentre, prospective cohort study.
    Lyu T; Cheung KS; Ni L; Guo J; Mu P; Li Y; Yang Q; Yu X; Lyu Z; Wu J; Guo H; Leung WK; Seto WK
    J Antimicrob Chemother; 2020 Nov; 75(11):3391-3394. PubMed ID: 32785699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surveillance of Helicobacter pylori resistance over 22 Years (2000-2021) in Northern Spain.
    Gómez-Ruiz de Arbulo M; Tamayo E; Bujanda L; Mendibil L; Mendiola J; Cilla G; Montes M
    J Glob Antimicrob Resist; 2023 Sep; 34():127-133. PubMed ID: 37433393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study.
    Poonyam P; Chotivitayatarakorn P; Vilaichone RK
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2859-2864. PubMed ID: 31554388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Best Practices for
    Graham DY
    Gastroenterol Hepatol (N Y); 2024 Mar; 20(3):159-168. PubMed ID: 38680170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and Treatment of
    Lee YC; Dore MP; Graham DY
    Annu Rev Med; 2022 Jan; 73():183-195. PubMed ID: 35084993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates.
    Graham DY
    Dig Dis Sci; 2023 May; 68(5):1691-1697. PubMed ID: 36856926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of Refractory
    Liou JM; Lee YC; Wu MS;
    Gut Liver; 2022 Jan; 16(1):8-18. PubMed ID: 33782215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.